47,346 Shares in United Therapeutics Corporation $UTHR Bought by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 47,346 shares of the biotechnology company’s stock, valued at approximately $25,653,000. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.11% of United Therapeutics at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Arjuna Capital grew its position in shares of United Therapeutics by 2.8% in the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after acquiring an additional 18 shares during the period. Sage Rhino Capital LLC increased its stake in shares of United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC raised its holdings in shares of United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after purchasing an additional 24 shares during the period. Meeder Advisory Services Inc. raised its holdings in shares of United Therapeutics by 4.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 26 shares during the period. Finally, Independent Advisor Alliance lifted its stake in United Therapeutics by 3.3% in the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 27 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on UTHR shares. Morgan Stanley set a $515.00 target price on United Therapeutics in a research note on Thursday, August 6th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

Insider Transactions at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $547.62, for a total transaction of $5,202,390.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,185,729.06. This trade represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,311,581.28. This trade represents a 34.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 434,275 shares of company stock valued at $234,984,268. Insiders own 8.60% of the company’s stock.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $521.00 on Friday. The company has a market capitalization of $22.35 billion, a P/E ratio of 18.64, a P/E/G ratio of 1.79 and a beta of 0.59. United Therapeutics Corporation has a 1 year low of $302.19 and a 1 year high of $609.35. The business’s 50 day simple moving average is $533.74 and its 200 day simple moving average is $537.53.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period last year, the firm earned $6.41 EPS. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.